The invention of Brilinta – a potential blockbuster drug to treat thrombotic disorders

Special Lecture hosted by IRIC & IRICoR
Lecture by John Dixon, Director, JD International Consulting Ltd., Leicestershire, UK
 

Tuesday, June 14 at 11:30 am, Lecture Hall S1-111 – Jean-Coutu Pavilion | Université de Montréal campus

John Dixon has 36 years experience in Pharmaceutical Research & Development across several therapeutic areas. He was Head of Medicinal Chemistry for 20 years at Fisons, Vice- President of Pre-Clinical R&D at Astra Charnwood for 4 years and Vice-President of Drug Discovery at AstraZeneca Charnwood for 9 years. As VP of AstraZeneca Charnwood he delivered 35 candidate drugs, most recently in the respiratory area. Currently, several Charnwood compounds are in Phase II and Phase III development. Brilinta/Brilique (ticagrelor), a potential blockbuster for thrombotic disorders, achieved marketing approval in Europe and final FDA approval on 20 July 2011. A second drug Cangrelor/ Kengrexal achieved both European and FDA marketing approval in 2015.

Upon retirement from AstraZeneca in July 2008, John became Director of JD International Consulting Ltd. His consultancies cover most aspects of drug discovery and early development in most therapy areas and in all types of organisations around the world.

John is a Fellow of the Royal Society of Chemistry and Member of the American Chemical Society and has served on several professional and academic advisory committees. In 2004, John was awarded an honorary D.Sc. from Loughborough University in the UK for outstanding contributions to Medical Science.

 

Lecture given in English ― No reservations required ― Free entrance ― Information: 514 343.6111, ext. 44666 ― conferences@iric.ca

 

© 2008-2020 IRICoR